Business Wire

MA-BLUECONIC

9.2.2021 14:04:12 CET | Business Wire | Press release

Share
BlueConic Helps Organizations Continue to Build First-Party Data Assets in the Wake of Third-Party Cookie Deprecation

BlueConic, the world’s leading pure-play customer data platform (CDP), today announced new functionality that enables customers to continue building legitimate first-party data assets amid rising third-party cookie and privacy-related data restrictions.

Google and Apple are pushing forward with plans to eliminate third-party cookies to crack down on widely used advertising technologies that collect, share, and sell customer data with little regulation and without consumers’ knowledge or consent. While this broad-strokes approach to fixing the problem is rightly rooted in bringing more transparency, choice, and control to consumers, it also inadvertently jeopardizes legitimate first-party data collection and the decade’s worth of progress companies have made toward recognizing visitors on the web and providing them with more relevant, personalized cross-channel experiences.

With this new functionality, BlueConic is giving companies the ability to centrally manage first-party server-side cookies to continue to build their first-party data assets and untether their marketing tactics from technologies that rely on third-party cookies. Collecting consented, first-party data in unified profiles helps companies power personalization tactics (e.g., relevant product recommendations, personalized offers and reminders etc.) on web channels – whether or not an individual identifies themselves. Similar to BlueConic’s end-to-end consent management capabilities, it will help customers navigate the complexity of data management as privacy regulations change.

Leveraging a centralized, easy-to-use console, BlueConic customers will be able to manage the implementation of first-party cookies across all of their web channels, without putting the onus on marketers or IT teams to coordinate multiple domains, manage various databases for each domain, or manage certificate renewals in their DNS. As a result, companies can continue capturing on-site data to enrich the unified customer profiles stored within their BlueConic database with confidence and utility. For instance, customers can:

  • Interact with consumers using ad blockers: An estimated 30% of all internet users now use ad blockers, which can be problematic for businesses trying to reach their audiences. Since these users are represented by persistent profiles in BlueConic, customers can continue to grow their audience.
  • Reduce false unique visitor counts: By eliminating first-party cookie expiration caps, business users can continue to recognize anonymous website visitors, track their behaviors over time, and deliver relevant, valuable experiences that are mutually beneficial to the company and the customer.
  • Improve identity management: With this new functionality, BlueConic ensures that companies, including multi-brand companies, can continue to build unified profiles using identity management capabilities from the time a customer is anonymous to the time they are known.

“BlueConic is focused on helping customers drive transformational growth through the collection and use of consented first-party data. Unfortunately, browser technology changes, which rightly prioritize consumer privacy over third-party tracking, have the potential to disrupt legitimate first-party data collection,” explains Bart Heilbron, CEO and co-founder of BlueConic. “This new functionality ensures our customers can continue to make first-party data the cornerstone of their customer-centric strategies as privacy policies proliferate.”

About BlueConic

BlueConic, the leading pure-play customer data platform, liberates companies’ first-party data from disparate systems and makes it accessible wherever and whenever it is required to transform customer relationships and drive business growth. Over 300 companies worldwide, including Hearst Newspapers, Heineken, ING, T-Mobile, UEFA, and VF Corp, use BlueConic to unify data into persistent, individual-profiles, and then activate it across customer touchpoints and systems in support of a wide range of growth-focused initiatives, including customer lifecycle orchestration, modeling and analytics, digital products and experiences, audience-based monetization, and more. BlueConic is a global company with offices in the US and Europe. Learn more at www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release

First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release

Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures

IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release

IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye